Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jodi K Maranchie

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
The Journal of Urology|February 27, 2014
Comparative outcomes in the management of the renal massJodi K Maranchie
The Journal of Urology|August 19, 2014
Epigenetic factors affect tumor initiation, progression and recurrenceJodi K Maranchie
Urologic Oncology|February 22, 2025
A Festschrift in Honor of Michael J. DrollerJodi K Maranchie
Urologic Oncology|February 19, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Urologic Oncology|March 26, 2017
Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Thompson JM, Nguyen QH, Singh M, Pavesic MW, Nesterenko I, Nelson LJ, Liao AC, Razorenova OVJodi K Maranchie
The Journal of Urology|May 22, 2020
Editorial CommentJodi K Maranchie
Urologic Oncology|June 25, 2026
Featured SUO Fellow: Soum Lokeshwar, MD MBAJodi K Maranchie
Urologic Oncology|March 26, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Urologic Oncology|February 19, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Urologic Oncology|February 19, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
The Journal of Urology|February 27, 2014
Comparative outcomes in the management of the renal massJodi K Maranchie
The Journal of Urology|August 19, 2014
Epigenetic factors affect tumor initiation, progression and recurrenceJodi K Maranchie
Urologic Oncology|February 22, 2025
A Festschrift in Honor of Michael J. DrollerJodi K Maranchie
Urologic Oncology|February 19, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Urologic Oncology|March 26, 2017
Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma. Thompson JM, Nguyen QH, Singh M, Pavesic MW, Nesterenko I, Nelson LJ, Liao AC, Razorenova OVJodi K Maranchie
The Journal of Urology|May 22, 2020
Editorial CommentJodi K Maranchie
Urologic Oncology|June 25, 2026
Featured SUO Fellow: Soum Lokeshwar, MD MBAJodi K Maranchie
Urologic Oncology|March 26, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Urologic Oncology|February 19, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Urologic Oncology|February 19, 2017
Basic/Translational Science Survey Section: Kidney CancerJodi K Maranchie
Pageof 7